As of June 25, 2026, a Phase 3 clinical trial titled "A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants" is listed as recruiting. The trial is registered under identifier NCT06904261 on ClinicalTrials.gov.
Note that this trial update concerns migalastat, not larazotide. The event data provided pertains specifically to migalastat, a compound studied for Fabry disease in pediatric patients aged 2 to under 12 years with amenable GLA variants.
The study is in Phase 3, indicating a later stage of clinical development. Its current status is recruiting, meaning the trial is actively seeking participants who meet eligibility criteria at this time.
No results or outcome data have been reported for this trial as of the listed date. The recruiting status reflects only that patient enrollment is ongoing, not that any efficacy or safety conclusions have been reached.
Readers interested in learning more about compounds referenced in trial updates like this can consult the compound overview page for additional background and context on regulatory status and research history.